Johnson & Johnson’s Acquisition of Crucell
October 07, 2010
Cravath represented Johnson & Johnson in connection with its October 6, 2010, agreement to acquire, through an affiliate, all outstanding equity of Crucell N.V. that it does not already own, for consideration of approximately €1.75 billion, or €24.75 per share, in a recommended cash tender offer.
The Cravath team included partner Robert I. Townsend and associates Brittain A. Rogers and Sarah R. Kahn on corporate matters and partner Eric W. Hilfers and associate Jarrett R. Hoffman on executive compensation and benefits matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, Harvard Law Schoolmagna cum laude
-
A.B., 1987, Harvard Collegemagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
A.B., 1995, Princeton University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
